Group 1 - Barclays has cut the price target for Blackstone Inc. (BX) from $164 to $126 while maintaining an Equal Weight rating, citing early uncertainty regarding the impact of AI on portfolio companies and lowering earnings estimates for business development companies due to reduced flow assumptions [1] - Blackstone Life Sciences (BXLS) announced a funding agreement to advance the clinical development of bleximenib, an investigational oral menin inhibitor for acute myeloid leukemia (AML), which is noted as a challenging ailment to treat with the lowest survival rates among leukemia types [2] - Johnson & Johnson and funds managed by BXLS will co-finance ongoing and future clinical trials of bleximenib in AML, marking the first co-funding agreement between BXLS and Johnson & Johnson [3] Group 2 - Blackstone Inc. operates through segments including Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions, providing investment and fund management services [3]

Core Insights - Bleximenib, an investigational selective menin inhibitor, demonstrates potential as a combination therapy for relapsed or refractory acute myeloid leukemia (AML) and newly diagnosed, intensive chemotherapy-ineligible AML [1][2] - The Phase 1b study shows promising efficacy and safety data, with an overall response rate (ORR) of 82% for relapsed or refractory AML and 90% for newly diagnosed patients [2][3] - The safety profile indicates a low rate of differentiation syndrome and no significant cardiac safety signals, supporting further investigation in Phase 2 and 3 studies [1][2][3] Company Overview - Johnson & Johnson is committed to addressing unmet medical needs in hematologic malignancies, focusing on innovative treatment options for AML [2][8] - The company is exploring the potential of bleximenib both as a monotherapy and in combination with standard care regimens in ongoing clinical trials [6][8] Industry Context - Acute myeloid leukemia is the most common type of acute leukemia in adults, characterized by low survival rates and poor patient outcomes, particularly in those with KMT2A gene rearrangements and NPM1 mutations [2][7] - The five-year survival rate for AML remains the lowest among leukemias, highlighting the urgent need for effective treatment options [7]